Favorable Response After Only One Cycle of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE in a Patient With Metastatic Merkel Cell CarcinomaMoghadam, Soroush Zarehparvar MD; Divband, Ghasemali MD; Shakeri, Sara MD; Aryana, Kamran MDClinical Nuclear Medicine: August 2019 - Volume 44 - Issue 8 - p 650–652 doi: 10.1097/RLU.0000000000002669 Interesting Images Buy Abstract Author InformationAuthors Article MetricsMetrics A 77-year-old man with a history of metastatic Merkel cell carcinoma and debilitating painful cutaneous lesions was referred to our nuclear medicine department for peptide receptor radionuclide therapy with 177Lu-DOTATATE as ultimate therapeutic option. Post-treatment whole body scan showed multiple zones of 177Lu-DOTATATE uptake in the metastatic regions, which revealed significant improvement within the next 10 days of therapy. Peptide receptor radionuclide therapy in metastatic Merkel cell carcinoma is an effective therapeutic option that should be considered in earlier stages of the disease. From the Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Received for publication December 26, 2018; revision accepted May 1, 2019. Conflicts of interest and sources of funding: none declared. Correspondence to: Kamran Aryana, MD, Nuclear Medicine Research Center, Ghaem Hospital, Mashhad, Iran. E-mail: Aryanak@mums.ac.ir. Online date: June 14, 2019 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.